Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets.

Pharmacogenetics and genomics - 1 Aug 2005

Kirchheiner Julia, Henckel Hanns-Benjamin, Franke Leonora, Meineke Ingolf, Tzvetkov Mladen, Uebelhack Ralf, Roots Ivar, Brockmöller Jürgen

Abstract excerpt

INTRODUCTION: CYP2D6 gene duplication causing ultrafast metabolism is one reason for failure in responding to CYP2D6-metabolized antidepressants. We studied the effect of the CYP2D6 duplication genotype on doxepin pharmacokinetics and platelet serotonin uptake and concentrations. METHODS: Pharmac...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Tricyclic
Share to Blood Platelets
Share to Cardiovascular Physiological Phenomena

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Gene Duplication

Share to Genotype

Share to Reference Values

Share to Serotonin

Source

Identifiers

PMID: 16007002
DOI: 10.1097/01.fpc.0000167331.30905.9e

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16007002-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets.PMID 16007002Read ↗

An observational study of Venlafaxine and CYP2D6 in clinical practice.Semantic proximity Read ↗

Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.Semantic proximity Read ↗

Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6.Semantic proximity Read ↗

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.Semantic proximity Read ↗

Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine.Semantic proximity Read ↗

PBPK modeling of the antidepressant doxepin incorporating CYP2D6 genotype for precision pharmacotherapy.Semantic proximity Read ↗

Patients with difficult-to-treat depression do not exhibit an increased frequency of CYP2D6 allele duplication.Semantic proximity Read ↗

Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication.Semantic proximity Read ↗

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.Semantic proximity Read ↗

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.Semantic proximity Read ↗

The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.Semantic proximity Read ↗

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.